New developments in antimicrobial use in sepsis

Current Pharmaceutical Design

Volumn 14, Issue 19, 2008, Pages 1912-1920

  Kaul, Daniel R ^a   Collins, Curtis D ^a   Hyzy, Robert C ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Antimicrobial therapy; Sepsis; Septic shock

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; COLISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; ICLAPRIM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; TELAVANCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACTEREMIA; BACTERIAL PNEUMONIA; CANDIDIASIS; CATHETER INFECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMUNICABLE DISEASE; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LUNG INFECTION; MONOTHERAPY; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SEPSIS; SKIN INFECTION; THROMBOCYTOPENIA; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDIASIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; METHICILLIN RESISTANCE; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 48249088012     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784980608     Document Type: Review

References (81)

1. Lever A, Mackenzie I. Sepsis: Definition, epidemiology, and diagnosis. BMJ 2007; 335: 879-83.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
3. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: The CUB-Rea Network. Am J Respir Crit Care Med 2003; 168: 165-72.
4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54.
5. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: 2976-84.
6. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007; 44: 87-93.
7. Kumar A, Robert D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
8. Shales DM, Gerding DN, John JF. Society for Healthcare Epidemiology of America and Infectious Disease Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584-99.
9. Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, Garfinkel B, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352: 468-75.
10. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-74.
11. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144: 309-17.
12. Davis SL, Perri MB, Donabedian SM, Manierski C, Singh A, Vager D, et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Micro 2007; 45: 1705-11.
13. Castaldo ET, Yang EY. Severe sepsis attributable to community-associated methicillin-resistant Staphylococcus aureus: An emerging fatal problem. Am Surg 2007; 73: 684-7.
14. Vayalumkal JV, Whittingham H, Vanderkooi O, Stewart TE, Low DE, Mulvey M, et al. Necrotizing pneumonia and septic shock: Suspecting CA-MRSA in patients presenting to Canadian emergency departments. CJEM 2007-9: 300-3.
15. Gonzalez BE, Rueda AM, Shelburne SA, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 2006; 27: 1051-6.
16. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2009; 46: 193-200.
17. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus: an antibiotic enters obsolescence. Clin Infect Dis 2007; 44: 1543-8.
18. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bactermia and endocarditis caused by Staphlococcus aureus. N Engl J Med 2006; 355: 653-65.
19. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: A review 4 years after first approval. Pharmacology 2008; 81: 79-91
20. Moellering RC, Jr. Linezolid: The First Oxazolidimone Antimicrobial. Ann Intern Med 2003; 138: 135-42.
21. Powers JH, Ross DB, Lin D, Soreth J, Wunderink RG, Kollef M, et al. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: The subtleties of subgroup analyses. Chest 2004; 126: 314-6.
22. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49: 2260,
23. Kollef NK Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: Retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intens Care Med 2004; 30: 388-94.
24. Tack KJ, Wilcox MH, Bouza E, Herr DH, Ijzerman MM, Croos-Dabrera RV, et al. Linezolid vs. vancomycin or oxacillin/dicoloxacillin for the treatment of catheter-related bloodstream infections. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL., 2007.
25. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8: 53-66.
26. Stein GE, Craig WA. Tigecycline: A critical analysis. Clin Infect Dis 2006; 43: 518-24.
27. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: Results of two double blind phase 3 comparison studies with vancomycin and aztreonam. Clin Infect Dis 2005; 41: S341-S53.
28. Anthony K, Fishman N, Linkin D, Gasink L, Edelstein P, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug resistant gram negative organisms treated with tige-cycline. Clin Infect Dis 2008; 46: 567-70.
29. Olsen Y, Rebuck J, Rupp M. Arthralgias and myalgias related to quinupristin/dalfopristin administration. Clin Infect Dis 2001; 32: e83-e6.
30. McDonald LC. Trends in antimicrobial resistance in health care associated pathogens and effect on treatment. Clin Infect Dis 2006; 42: S65-S71.
31. Pop-Vicas AE, D'Agata EM. The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis 2005; 40: 1792-8.
32. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470.
33. Fournier P, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42: 692-9.
34. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
35. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: The renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-21.
36. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-83.
37. Linden P, Paterson D. Parenteral and inhaled colistin for treatment of ventilator associated pneumonia. Clin Infect Dis 2006; 43: S89-S94.
38. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium cotistimethate: Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-68.
39. Rodloff AC, Leclercq R, Debbia EA, Canton R, Oppenheim BA, Dowzicky MJ. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clin Micro Infect 2008; 14: 307-14.
40. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: A cautionary report. J Antimicro Chemother 2007; 59: 128-31.
41. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27: 1198-201.
42. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48: 3136-40.
43. Rahal J. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43: S95-9.
44. Dubois V, Arpin C, Melon M, Melon B, Andre C, Frigo C, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: Efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J Clin Micro 2001; 39: 2072-8.
45. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
46. Harbarth S, Nobre V, Pittet D. Healthcare epidemiology: Does antibiotic selection impact patient outcome? Clin Infect Dis 2007; 44: 87-93.
47. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 1996; 80: 126-37.
48. Owens RC, Banevicius MA, Nicolau DP, Nightingale CH, Quintiliani R. In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates. Antimicrob Agents Chemother 1997; 41: 2596-8.
49. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. [beta] lactam monotherapy versus [beta] lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomised trials. BMJ 2004; 329: 668.
50. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4: 519-27.
51. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: Systematic review and meta-analysis. BMJ 2003; 326: 1111.
52. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: A meta-analysis. Lancet Infect Dis 2002; 2: 231-42.
53. National Comprehensive Cancer Network: Prevention and Treatment of Cancer Related Infections. 2008 [cited 2008 February 13]; Available from: Http://www.nccn.org/professionals/physician_gls/PDF/ infections.pdf.
54. Damas P, Garweg C, Monchi M, Nys M, Canivet JL, Ledoux D, et al. Combination therapy versus monotherapy: A randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779]. Crit Care 2006; 10: 52-9.
55. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41: 149-58.
56. Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006; 130: 787-93.
57. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
58. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: A systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006; 25: 419-25.
59. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9: 499-511.
60. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
61. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
62. Laverdiere M, Labbé AC, Restieri C, Rutstein C, Heyland D, Madger S, et al. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J Crit Care 2007; 22: 245-50.
63. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
64. Ruan SY, Lee LN, Jerng JS, Yu CJ, Hsueh PR. Candida glabrata fungaemia in intensive care units. Clin Microbiol Infect 2008; 14: 136-40.
65. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: Global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10 Suppl 1: 11 -23.
66. Burn AK, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, McCarthy DI, et al. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients. J Clin Microbiol 2004; 42: 5846-9.
67. Drew RH. Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis? Ann Pharmacother 2007; 41: 690-2.
68. Sobel JD, Revankar SG. Echinocandins - first-choice or first-line therapy for invasive candidiasis? N Engl J Med 2007; 356: 2525-6.
69. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-92.
70. Bad bug, no drugs: As antibiotic R&D stagnates, a public health crisis brews Alexandria, VA: Infectious Disease Society of America 2004.
71. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-68.
72. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated. skin and skin-structure infections. Clin Infect Dis 2008; 46: 647-55.
73. http://clinicaltrials.gov/ct2/show/NCT00423657. [cited 2008 March 22]; Available from: Http://clinicaltrials.gov/ct2/show/NCT00423 657.
74. Lin SW, Carver PL, DePestel DD. Dalbavancín: A new option for the treatment of gram-positive infections. Ann Pharmacother 2006; 40: 449-60.
75. http://clinicaltrialsgov/ct2/show/NCT00543608?recr=open&cond= nosocomial+infections&rank=15 [cited 2008 March 22].
76. Tenover F, Moellering JP, The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphyococcus aureus. Clin Infect Dis 2007; 44: 1208-15.
77. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack K. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42: 597-607.
78. Boyer EW, Shannon M. Serotonin syndrome. N Engl J Med 2005; 352: 1112-20.
79. Komatsuzawa H, Ouhara K, Kawai T, Yamada S, Fujiwara T, Shiba H, et al. Susceptibility of periodontopathogenic and cariogenic bacteria to defensins and potential therapeutic use of defensins in oral diseases. Curr Pharm Des 2007; 13(30): 3084-95.
80. Meyer JE, Harder J. Antimicrobial peptides in oral cancer. Curr Pharm Des 2007; 13(30): 3119-30.
81. Reutershan J. CXCR2-the receptor to hit? Drug News Perspect. 2006 Dec; 19(10): 615-23.